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ABSTRACT: SecA is the peripheral subunit of the preprotein translocase of Escherichia coli. SecA consists
of two independently folding domains, i.e., the N-domain bearing the high-affinity nucleotide binding
site (NBS-I) and the C-domain that harbors the low-affinity NBS-II. ATP induces SecA insertion into
the membrane during preprotein translocation. Domain-specific monoclonal antibodies (mAbs) were
developed to analyze the functions of the SecA domains in preprotein translocation. The antigen binding
sites of the obtained mAbs were confined to five epitopes. One of the mAbs, i.e., mAb 300-1K5, recognizes
an epitope in the C-domain in a region that has been implicated in membrane insertion. This mAb, either
as IgG or as Fab, completely inhibits in Vitro proOmpA translocation and SecA translocation ATPase
activity. It prevents SecA membrane insertion and, more strikingly, reverses membrane insertion and
promotes the release of SecA from the membrane. Surface plasmon resonance measurements demonstrate
that the mAb recognizes the ADP- and the AMP-PNP-bound state of SecA either free in solution or
bound at the membrane at the SecYEG protein. It is concluded that the mAb actively reverses a
conformation essential for membrane insertion of SecA. The other mAbs directed to various epitopes in
the N-domain were found to be without effect, although all bind the native SecA. These results demonstrate
that the C-domain plays an important role in the SecA membrane insertion, providing further evidence
that this process is needed for preprotein translocation.
SecA is the central component of the preprotein translo-
case in Escherichia coli (for reviews, see ref 1, 2). Prepro-
tein translocase is a multimeric membrane protein complex
that in addition to SecA consists of the integral membrane
proteins SecY, SecE, and SecG as stable subunits (3-5),
and SecD and SecF as accessory proteins (6, 7). The
dynamic distribution of SecA between the cytosol and the
membrane is determined by the amount of integral translo-
case subunits present in the membrane and by growth
conditions (8-11). The heterotrimeric SecYEG complex
constitutes a high-affinity membrane binding site for SecA
(3, 12), and the SecA bound at these sites exposes a carboxy-
terminal domain to the periplasmic face of the membrane
(8). SecA may also directly bind to the phospholipids at
the membrane surface that constitute a binding site with low
affinity (13, 14). SecA is required for the productive binding
of preproteins to the translocase (3, 4). It interacts with the
signal sequence and with a part of the mature preprotein (15,
13) but also binds SecB, a molecular chaperone that is
specific for preprotein translocation (3). A key feature of
the SecYEG-bound SecA is its ATPase activity that is
stimulated by preproteins (13). SecA couples the hydrolysis
of ATP to the translocation of the preprotein across the
membrane. SecA is a large protein of 102 kDa, and not
only exists (16) but also functions (17) as a stable ho-
modimer. Each of the protomers comprises two indepen-
dently folding domains of similar size, which have been
termed the amino (N) and the carboxy (C) terminal domains
(18). The N-domain contains a high-affinity (KD,ADP  0.15
íM) nucleotide binding site (NBS-I),1 whereas the C-domain
contains a site that binds nucleotides with low affinity (KD,ADP
 340 íM, NBS-II) (19, 20). Both NBSs are able to bind
ATP independently in Vitro, whereas mutants in either site
inhibit the translocation ATPase activity of SecA completely,
indicating that both sites are essential for and act in a
concerted manner in the SecA-mediated translocation (20-
22). During translocation, preproteins are pushed across the
membrane in steps of about 2-3 kDa (23). This process is
thought to be driven by nucleotide-modulated cycles of
membrane inserted SecA (24, 25, 14). In the presence of
preprotein, the binding of ATP (or the nonhydrolyzable ATP
analog AMP-PNP) drives the insertion of SecA into SecA-
depleted membranes in a SecYEG-dependent fashion. This
gives rise to a number of proteinase resistant SecA fragments
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using uniformly 35S-labeled SecA (26, 14) or a 30-kDa
carboxy-terminal fragment using 125I-SecA (24-26; Figure
1). Based on the observation that ATP hydrolysis stimulates
the de-insertion of the 30-kDa 125I-SecA fragment, and that
a second ATP molecule has to be hydrolyzed to release the
SecA from the membrane, it has been suggested that the de-
insertion of SecA is an essential part of the preprotein
translocation cycle (24, 25). However, in 35S-SecA-
reconstituted membranes, about 50-60% of the 35S-SecA
can be released by unlabeled SecA independent of protein
translocation and the remaining SecA seems to be stably
inserted and fully functional in preprotein translocation (14),
suggesting, that the de-insertion of SecA may not to be a
prerequisite for preprotein translocation.
The mechanistic details, how the nucleotide-induced
conformational changes in SecA are coupled to preprotein
translocation, are only poorly understood. Differential
scanning calorimetry and dynamic light scattering experi-
ments with soluble SecA (18) indicate that the AMP-PNP-
bound state of SecA has a more extended conformation than
the ADP-bound state. The ADP-bound state may resemble
the membrane de-inserted, surface-bound state of SecA,
whereas the more extended AMP-PNP-bound state possibly
corresponds to the membrane inserted conformation. Bind-
ing of nucleotides to NBS-I changes the interaction between
the N- and C-domains (18), possibly by closing and opening
of a cleft between both domains. To provide further
information about the functions of the C- and N-domains,
we have raised monoclonal antibodies against specific parts
of SecA. One mAb recognizes an epitope that is confined
to the 30-kDa carboxyl-terminal region of SecA that has been
shown to insert into the membrane (26). This mAb ef-
ficiently inhibits in Vitro translocation and blocks the SecA
translocation ATPase activity. Inhibition is due to the
prevention of SecA membrane insertion and, more strikingly,
the reversal of the membrane inserted state of SecA. It is
concluded that the mAb inhibits preprotein translocation by
interfering with a membrane inserted conformation of SecA.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Growth Media. Unless indicated
otherwise, strains were grown in Luria Bertani (LB) broth
or on LB-agar supplemented with 50 íg of ampicillin/mL,
0.5% (w/v) glucose, or 1 mM isopropyl 1-thio-â-D-galacto-
pyranoside, as required. SecYEG overproduction was done
in SF100 freshly transformed with pET340 (YEG+), SecA
in JM109 and NO2947 containing pMKL18, SecB in
NO2947 (Table 1) containing pAK330 (27), and proOmpA
in E. coli strain MM52 transformed with pTAQpOA (gift
of N. Nouwen).
Materials. SecA, SecB, and proOmpA were isolated as
described (28-30, respectively). Purified SecA was labeled
with carrier-free 125I (Radiochemical Centre, Amersham,
U.K.) to a specific activity of about 5  104 cpm/pmol
according to the following procedure: SecA (100 íg) in
buffer A (50 mM TrisHCl, pH 8.0, 50 mM KCl, 5 mM
MgCl2, and 10% glycerol) was transferred to a reaction vial
coated with IODO-GEN Iodination Reagent (Pierce, Rock-
ford, IL). The reaction was started by adding 2 íL of K125I
(200 íCi), incubated for 15 min at room temperature, and
terminated by transferring the mixture into a new reaction
vial containing dithiothreitol (DTT) at a final concentration
of 10 mM. Free iodine was removed by chromatography
on a PD-10 Sephadex column (Pharmacia LKB Biotech AB,
Uppsala, Sweden) which was prewashed with buffer A,
containing 1 mM DTT.
Inverted inner membrane vesicles (IMV; 31) were prepared
from E. coli D10 and SF100 which was transformed either
with pET324 (8) as a control or with pET340 (SecYEG+;
Table 1). The fusion proteins cro-â-galactosidase-SecA-
(323-706) and cro-â-galactosidase-SecA(149-323) were
purified from strain POP2136 containing the cIts857 repres-
sor harboring the plasmids pET111 and pET135, respectively.
Monoclonal antibodies were produced as hybridoma super-
natants (MCA development b.v. Groningen, The Nether-
lands) or as ascites (Eurogentec, Gent, Belgium) and purified
by protein G-Sepharose 4 Fast Flow affinity chromatogra-
phy as recommended by the company (Pharmacia). Fab
fragments were obtained using the ImmunoPure Fab prepara-
tion kit of Pierce as recommended. AMP-PNP was purified
of contaminating ADP as described (18). Anti-mouse IgG
Fcç was from Pharmacia (Biosensor AB, Uppsala, Sweden).
All chemicals were from Sigma (St. Louis, MO) if not stated
otherwise.
Construction and Expression of the Fusion Gene lacZ-
secA. A DNA fragment encoding a truncated SecA molecule
was obtained by digestion of pMKL18 encoding wild-type
SecA with SalI-PstI or with EcoRV-SalI. The fragments
were made blunt by T4-polymerase/exonuclease treatment
and cloned in-frame with lacZ in the multiple cloning site
of pEX1 and pEX2, respectively. The pEX plasmids contain
a synthetic operon expressing a 117 000 Da cro-â-galac-
tosidase hybrid protein under control of the PR promoter of
bacteriophage ì (32). All DNA manipulation techniques
were essentially done as described (33). The resulting
constructs pET111 and pET135 were transformed into strain
POP2136 and grown at 30 °C in LB. An overnight culture
was diluted 1:100 in 200 mL of LB and grown at 30 °C for
2 h, after which the fusion protein expression was induced
by a shift to 42 °C. After 3 h, the cells were harvested by
centrifugation. The pellet was resuspended in Laemmli
sample buffer (34) and boiled for 5 min to lyse the cells.
Debris was removed by centrifugation at 14000g, and the
lysate was loaded onto preparative 7.5% SDS-PAGE
(sodium dodecyl sulfate-polyacrylamide gel electrophoresis,
34). After electrophoresis, the gel was stained by 0.3 M
CuCl2, and a protein band of approximately 150 kDa was
excised and electroeluted overnight at 90 V. The protein
solution was washed with phosphate-buffered saline and
concentrated by centrifugation in a 10 000 NMWL filter unit
(Millipore, Bedford, MA). Protein concentration was de-
termined as described (35, 36).
Immunization. At day 0, BALB/c mouse 322, 323, and
300 were immunized by injection intraperitoneally with 50
íg of the â-galactosidase-SecA(323-706) and â-galactosi-
dase-SecA(149-323) fusion proteins and with purified
wild-type SecA mixed with complete Freund’s adjuvant,
respectively. On day 54 and 90, the mice were injected
intraperitoneally with a second 50 íg of protein with
incomplete Freund’s adjuvant. On day 104, a blood sample
was taken from the mice to monitor the presence of SecA-
and â-galactosidase-specific antibodies. After 110 days, the
mice were boosted intravenously with 50 íg of purified wild-
type SecA to activate B lymphocytes that produce SecA-
specific antibodies. Three days later, lymphocytes were
isolated from the spleen for fusion with SP20 myeloma cells
by standard techniques (37).
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Selection of MAbs. Hybridomas were selected on the basis
of a strong positive reaction in an ELISA (enzyme linked
immunoadsorbent assay) with purified wild-type SecA and
with the corresponding fusion protein and a negative reaction
with â-galactosidase. A second selection was carried out
on the basis of a strong positive reaction with wild-type SecA
in cell extract on immunoblot analysis. Hybridomas showing
positive reactions of the desired specificity were cloned by
the limiting dilution technique at a density of 3-5 cells/
well and recloned at a density of 0.3 cell/well. Selected
cultures were grown in bulk, and the culture supernatant of
selected hybridomas was used for the characterization of the
mAbs. The immunoglobulin (Ig) subclasses of the mAbs
were determined by ELISA with peroxidase-conjugated
subclass-specific antisera (ITK Diagnostics B. V., Uithoorn,
The Netherlands).
Epitope Mapping. The epitopes of the mAbs were
deduced from their affinity for purified truncated SecA
molecules in an ELISA assay and whole cell extracts
containing â-galactosidase-SecA fusion proteins analyzed
by immunoblotting. The amino- and carboxy-terminal
truncated SecA molecules were constructed and purified as
described previously (38). â-Galactosidase-SecA fusion
proteins for the epitope mapping were constructed as follows.
A secA fragment was obtained by digestion of pMKL18
encoding wild-type SecA with SalI-KpnI or SalI-SnaBI.
The fragments were made blunt by T4-polymerase/exonu-
clease treatment and cloned in frame with lacZ in the multiple
cloning site of pEX1. The resulting constructs pET112 and
pET113 were transformed into strain POP2136 and expressed
as described (see above).
In Vitro Translocation. In Vitro translocation of 35S-
labeled proOmpA was performed as described (3) with 20
íg/mL SecA, 32 íg/mL SecB, 2 mM ATP, 10 mM
phosphocreatine, and 50 íg/mL creatine kinase in translo-
cation buffer [50 mM HEPES-KOH, pH 7.6, 30 mM KCl,
2 mM DTT, 0.5 mg/mL bovine serum albumin (BSA), and
2 mMMgOAc]. 35S-Labeled proOmpA was diluted 50-fold
from a solution of 8 M urea and 50 mM Tris-HCl, pH 7.6,
followed by the addition of E. coli IMV at a final protein
concentration of 1.7 mg/mL or urea-treated IMV (0.2-0.5
mg/mL). Reactions were incubated for 30 min at 37 °C,
and stopped by cooling on ice. Samples were treated with
proteinase K (0.1 mg/mL) for 15 min on ice. Subsequently,
the samples were precipitated with 6.7% (w/v) trichloroacetic
acid, washed with acetone, and analyzed by SDS-PAGE
and autoradiography.
SecA Translocation and Endogenous ATPase Assay. The
translocation ATPase activity of SecA using urea-treated
vesicles (28) was measured as described (39) except that the
reactions were supplied with 32 íg/mL SecB. The endog-
enous SecA ATPase activity (i.e., in the absence of vesicles
and preprotein) was determined in 50 íL of 50 mM TrisHCl,
pH 8.0, 50 mM KCl, 5 mM MgCl2, 1 mM DTT, 0.5 mg/mL
BSA, 17 íg/mL SecA, and 1 mM ATP and incubated for 3
h at room temperature.
Insertion and De-insertion of Iodinated SecA. 125I-SecA
(16 nM) was incubated 30 min in translocation buffer
supplemented with proOmpA, SecB, and urea-treated YEG+
IMV (200 íg/mL) in the presence or absence of mAb and
AMP-PNP or ATP at 0 and 37 °C, respectively. The reaction
was terminated by proteinase K digestion as described (24).
The digests were analyzed by 12% SDS-PAGE and by
phosphor imaging (Phosphor Imager, Molecular Dynamics,
Sunnyvale, CA) and quantitated using the program Image
Quant V3.3 of the same company.
Membrane Binding of SecA. 125I-SecA (16 nM) was
incubated 20 min in translocation buffer supplemented with
proOmpA, SecB, 1 mM AMP-PNP, and urea-treated YEG+
IMV (200 íg/mL) at 37 °C (3). To remove unbound SecA,
the sample was centrifuged through 0.2 M sucrose in
translocation buffer (10 min, 30 psi in a Beckman airfuge at
4 °C), and the membranes were resuspended in 80 íL of
1.25  translocation buffer supplemented with 1.25 mM
AMP-PNP. To these samples was added mAb IgG (66 nM)
or SecA (200 nM) and the volume adjusted to 100 íL.
Membrane-bound SecA was separated from soluble SecA
by centrifugation through a sucrose cushion as described (see
above). The 125I-SecA in the supernatant and pellet were
quantified in a gamma counter.
Surface Plasmon Resonance (SPR). Real time detection
of antibody-antigen binding and kinetic analysis at 25 °C
were performed using the BIAlite surface plasmon resonance
based system (Pharmacia Biosensor). The principle and
application of the system employing the method of surface
plasmon resonance detection has been described by Karlsson
et al. (40). MAb 300-1K5 (50 íg/mL in 10 mM sodium
acetate, pH 4.8) was immobilized to the sensor chip CM5
by amine coupling according to the standard procedure until
2300 resonance units (RU) were coupled (1000 RU corre-
sponds to approximately 1.0 ng/mm2 or 6 mg/mL; see
BIAlite manual). Binding of 120 nM SecA, 0.425 mg/mL
YEG+ IMV, or 0.25 mg/mL urea-treated YEG+ IMV was
performed at 10 íL/min in buffer HKM (50 mM HEPES-
KOH, pH 7.5, 100 mM KCl, 5 mM MgCl2, and 0.002%
surfactant P20) and 1.6 mM ADP or AMP-PNP which
saturates both NBSs. The association of SecA was followed
for 180 s, and the dissociation in the presence of the same
concentration of nucleotide was followed for 200 s. Re-
generation of the sensor chip after each analysis cycle was
performed by injection of 12 íL of 1 M diethanolamine,
pH 9.0, followed by the continuous flow of buffer HKM
buffer. A control CM5 sensor chip with the same history
of treatment as the CM5-300-1K5 chip, apart from the
addition of 300-1K5 during the immobilizing step, was used
to determine the background binding. The obtained data
were subtracted from the data obtained by the 300-1K5
sensor. All experiments were repeated 4-10 times, and the
results were averaged. A second CM5 sensor chip with 2000
Ru immobilized anti-mouse IgG Fcç (Pharmacia Biotech)
was used to capture the mAbs against SecA and subsequently
to measure the binding of SecA.
The change in the surface plasmon wave vector, ksp, is
determined by the change in the dielectric constant and
thickness of the polymer layer of biological molecules as
follows:
where ¢kpsp is the contribution of the polymer layer to the
plasmon wave vector, rm is the real part of the dielectric
constant of the metal layer, s and p are the dielectric
constants of the solution and the polymer layer, respectively,
dp is the thickness of the polymer layer, and k0 is the wave
vector of light in vacuum (41).
¢kpsp )
k0( rmsrm + s)2(p - rms - rm)[ 1(-rms)1/2](p - sp )2ƒdpì (1)
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The complex effective refractive index of the surface
plasmon (Neff) depends on the angle of reflection (ı) as
where np is the refractive index of the prism. It should be
noted that the dielectric constant is the square root of the
refractive index.
All sensograms were fitted by nonlinear regression as-
suming a A + B1 + B2 T AB1 + AB2 model for the
binding of SecA to IgG, using the Bia-evaluation program
provided by Pharmacia. Under results, only the association
rate constant ka (s-1 M-1), the dissociation rate constant kd
(s-1), and the dissociation constant KD (M-1) for the major
compound (84%) are shown.
RESULTS
Production and Epitope Mapping of MAbs against SecA.
To study the structure and function of the amino- and
carboxy-terminal domains of SecA, monoclonal antibodies
were developed against intact SecA, and against cro-â-
galactosidase fusions to amino acid residues 323-706 and
149-323 of SecA. Hybridoma supernatants producing
antibodies raised against the three proteins were selected for
binding the intact SecA, the respective SecA fragment, but
not the cro-â-galactosidase fusion protein in an ELISA. Ten
epitopes of 14 selected mAbs were further characterized with
isolated and purified SecA fragments of known polypeptide
sequence (42) and with some additional cro-â-galactosidase-
SecA fusion proteins (Tables 1 and 2). The epitopes of the
mAbs were refined to five areas on the polypeptide of SecA
(Figure 1). The four mAbs obtained from the immunization
with the intact SecA (e.g., hybridoma fusion 300, mAb 1K5
in Table 2) all recognize an epitope confined to a carboxy-
terminal area containing amino acid residues 720-790. The
mAbs obtained from cro-â-galactosidase-SecA(149-323)
fusion protein recognize an epitope which is at least partly
confined in the amino acid sequence 149-237 (e.g., hybri-
doma fusion 323, mAb 1K1; Table 2). The mAbs obtained
from cro-â-galactosidase-SecA(323-706) fusion protein
recognize three epitopes that are at least partly located in
the amino acid sequence 323-441, 438-441, and 502-558
(e.g., hybridoma fusion 322, mAbs 1K1, 2E9, and 1B10,
respectively; Table 2). Four mAbs were taken into produc-
tion and purified from hybridoma supernatant (322-1K1 and
322-2E9) or from ascites (300-1K5 and 323-1K1). Each of
these mAbs recognizes SecA as a single band on immuno-
blots of IMV (shown for 323-1K1, 322-1K1, and 300-1K5
in Figure 2, lanes 3-5, respectively).
ELISA and dot immunoblot were used to access whether
any of the mAbs was able to discriminate between denatured
and native SecA. SecA was either directly applied to the
ELISA or dot immunoblot or first denatured by boiling in
Laemmli SDS sample buffer and incubated with the mAbs.
Table 1: Escherichia coli Strains and Plasmids
strains genotype source or reference
JM109 recA1, endA1, gyrA96, thi-, hsdR17, relA1, supE44, ì- , ¢(lac-proAB),
[F′, traD36, proAB, lacIq ¢M15]
46
POP2136 F- ara D139 ¢(lac)U169 thiA rspL relA flaB cIts857 47
SF100 F- ¢(lac)X74 galE thiA rspL (strA) ¢phoA (PVuII) ¢ompT 48
NO2947 ¢lac[IPOZYA] araD139 ¢[ara-leu]7697 galU galK rpsL recA56 srl::Tn10 rkmk K. Linton
MM52 secA51ts 49
D10 rna10, relA1, spoT1, metB1 30
plasmids description source or reference
pMKL18 wild-type secA 50
pET111 secA containing aaa 323-706 in pEX1 this work
pET112 secA containing aa 323-558 in pEX1 this work
pET113 secA containing aa 323-831 in pEX1 this work
pET135 secA containing aa 149-323 in pEX2 this work
pEX1, 2, 3 Ampr PR promoter of phage ì and cro-lacZ gene fusion with
multiple cloning site in all three reading frames
32
pET340 secY, secE, secG in pTRC99A 8
a aa is amino acids.
Neff ) np sin ı (2)
Table 2: Characterization and Epitope Mapping of the MAbs
against SecA
antigen
149-323 323-706 323-706 323-706 1-901
mAbsSecA
fragment 323-1K1 322-1K1 322-2E9 322-1B10 300-1K5
323-558 - + + + -
323-706 - + + + -
323-831 - + + + +
149-323 + - - - -
1-790 + + + + +
1-720 + + + + -
1-502 + + + - -
1-441 + + + - -
1-237 + - - - -
267-901 - + + + +
438-901 - - + + +
epitopeb 149-237 323-441 438-441 502-558 720-790
IgG subclass IgG2a IgG2a IgG1 IgG1 IgG1
a Numbers refer to the amino acid sequence of SecA. +, reaction;
and -, no reaction on ELISA. b Since the mAbs seem to bind native
SecA preferentially, it cannot be excluded that other amino acids outside
the determined epitope area contribute to the mAb binding site.
FIGURE 1: Schematic representation of SecA domains, ligand
binding sites, epitopes of the mAbs, and the 30-kDa membrane-
inserting fragment of SecA (26). NBS is nucleotide binding site.
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The mAbs against the epitope area, 720-790 (300-1K5),
438-441 (322-2E9), and 149-237 (323-1K1), bind native
SecA very well and denatured SecA to a lesser extent (Table
3 and Figure 3). These mAbs were also able to recognize
SecA in a surface plasmon resonance biosensor assay, where
the purified IgG was bound by anti-mouse IgG Fcç im-
mobilized on the surface of a sensor chip and the SecA
flowing passed the sensor surface (Table 3). SPR detects
changes in the refractive index of the surface layer of a
solution in contact with the sensor chip (for a review, see
ref 41). The KD is in the nanomolar range for all mAbs
tested. However, the association rates of mAb 323-1K1 and
322-2E9 are slower than that of 300-1K5, which is partly
compensated by a decreased dissociation rate compared to
300-1K5. It can be concluded that the mAbs recognize
native SecA and to a lesser extent denatured SecA.
A dot immunoblot was used to access whether any of the
mAbs was able to recognize the membrane-bound SecA.
IMVs were directly applied to the dot immunoblot and
incubated with the mAbs. All mAbs apart from mAb 322-
1K1 (323-441) were able to bind SecA in this assay (Figure
4), indicating either that their epitopes are accessible in the
membrane-associated form of SecA or that the vesicles were
sufficiently disrupted to expose their epitopes.
In Vitro Preprotein Translocation Is Inhibited by MAb
300-1K5. A series of mAb dilutions was used to assay their
effect on the in Vitro translocation of proOmpA in wild-
type E. coli D10 and YEG+ vesicles bearing endogenous
SecA (not shown) and in urea-treated vesicles supplied with
SecA (Figure 5). At a 2-fold molar excess of mAb to SecA,
mAb 300-1K5 inhibited the proOmpA translocation com-
pletely irrespective of whether the vesicles were treated with
urea. To exclude that inhibition is caused by cross-linking
of the SecA dimer (17) by the bivalent IgG molecules, Fab
FIGURE 2: Immunolabeling of SecA in vesicles. E. coli D10 vesicles
(9 íg) were analyzed on a 10% SDS-PAGE and stained with
Coomassie brilliant blue (lane 1) or immunoblotted. Immunoblots
were developed with a pAb against SecA (lane 2), mAb 323-1K1
(lane 3), mAb 322-1K1 (lane 4), or mAb 300-1K5 (lane 5). On the
left, the positions and molecular masses of prestained markers (Bio-
Rad) are indicated. MAb 322-1K1 recognizes denatured SecA only
poorly, and therefore substantial background staining is visible in
lane 4.
Table 3: Native SecA Binding by the MAbs in ELISA and SPR in
the IgG Capturing Modea
ELISAb SPRc
mAb SecAN SecAD ka (s-1 M-1) kd (s-1)
300-1K5 100 20 2.5  105 ( 6  103 1  10-3 ( 7  10-5
322-2E9 106 18 8  104 ( 2  103 e10-4
322-1K1 66 6 nd nd
323-1K1 122 35 5.6  104 ( 1  103 2  10-3 ( 8  10-5
a The binding of SecA to the anti mouse IgG Fç was negligible.
bA solution of 50 íg/mL SecA was coated on ELISA; the primary
antibody concentration was 15 íg/mL. The reaction of mAb 300-1K5
was set at 100%. c The dissociation rate is a combination of the release
of SecA from the mAb and the release of the mAb from the anti mouse
IgG Fcç. d nd is not done.
FIGURE 3: Dot immunoblot analysis of the accessibility of the mAb
epitopes in native and SDS-denatured SecA. Purified native SecA
and SDS-denatured SecA (250 ng/dot) were analyzed on a dot
immunoblot with hybridoma supernatant of the mAbs. Lane 1,
normal mouse serum (1:1000) in 1% BSA, 0.5% Tween 20 in TBS;
lane 2, pAb against SecA (1:20 000) in 1% BSA, 0.5% Tween 20
in TBS; lane 3, mAb 323-1K1 (epitope 149-237); lane 4, mAb
322-1K1 (323-441); lane 5, mAb 322-2E9 (438-441); lane 6, mAb
300-1K5 (720-790). The blot was developed using a chemilumi-
nescence kit (Tropix).
FIGURE 4: Dot immunoblot analysis of the accessibility of the mAb
epitopes in IMV of E. coli KM9. Buffer, IMV concentration
normalized with respect to SecA, and the same amount of purified
SecA were analyzed on a dot immunoblot with hybridoma
supernatant of the mAbs. Lane 1, mAb 300-1K5 (epitope 720-
790); lane 2, mAb 323-2B10 (502-558); lane 3, mAb 322-2E9
(438-441); lane 4, mAb 322-1K1 (323-441); lane 5, mAb 323-
1K1 (149-237); lane 6, normal mouse serum (1:1000) in 1% BSA,
0.5% Tween 20 in TBS. The blot was developed using a
chemiluminescence kit (Tropix)
FIGURE 5: Effect of mAbs on the in Vitro translocation of proOmpA
into IMV. Translocation of 35S-proOmpA into urea-treated E. coli
D10 vesicles and 0.1 íM SecA was assayed in the presence of
increasing concentrations IgG (A, C) or Fab (B, D) of mAb 323-
1K1 (A, B) and mAb 300-1K5 (C, D). Preprotein translocation in
the absence of antibody (lane 1); in the absence of ATP (lane 2);
in the absence of SecA (lane 3); and in the presence of 0.1, 0.2,
0.4, and 0.8 íM antibody (lanes 4 up to 7, respectively).
Carboxy-Terminal Domain of SecA Biochemistry, Vol. 36, No. 30, 1997 9163
fragments were prepared by papain digestion. The Fab
fragments of mAb 300-1K5 also inhibited proOmpA trans-
location (Figure 5D). The other mAbs and their correspond-
ing Fabs showed only minor effects on the in Vitro
translocation of proOmpA (shown for mAb 323-1K1 in
Figure 5A,B). It is concluded that the mAb against the
C-domain inhibits the preprotein translocation reaction, and
this is not caused by cross-linking of the SecA dimer.
Translocation ATPase ActiVity of SecA but Not Its En-
dogenous ATPase ActiVity Is Inhibited by MAb 300-1K5. The
translocation ATPase activity of SecA was assayed in the
presence of increasing concentrations of mAb, using proOm-
pA as substrate. At a 3-fold excess, mAb 300-1K5 IgG
inhibited the translocation ATPase activity completely
(Figure 6), whereas the Fab stimulated the activity when
present at substoichiometric amounts but inhibited the
reaction completely at a 10-fold excess relative to SecA
(Figure 6). The antibody had no effect on the endogenous
ATPase activity (results not shown). The other mAbs show
a slight stimulation of the translocation (Figure 6, inset) and
endogenous ATPase activity of SecA (results not shown).
Summarizing, the mAb against the C-domain inhibits the
translocation but not the endogenous ATPase activity of
SecA.
MAb 300-1K5 Interferes with SecA Membrane Insertion
and De-insertion. SecA inserts into the membrane in the
presence of ATP and preprotein or in the presence of a
nonhydrolyzable ATP analogue such as AMP-PNP (24, 14).
Membrane insertion is assayed as the formation of a 125I-
labeled 30-kDa SecA domain that is inaccessible to proteases
(24). We used this assay, both under translocation (ATP)
and under non-translocation (AMP-PNP) conditions, to
analyze the influence of the mAbs on the membrane insertion
and subsequent de-insertion of SecA. MAb 300-1K5 inhibits
the insertion of SecA under both conditions (Figure 7), albeit
the effect is somewhat weaker under translocation conditions
(Figure 7C). The other mAbs showed no inhibition of the
insertion of SecA (Figure 7). To substantiate the inhibition
of membrane insertion by mAb 300-1K5, we followed the
formation of the 30-kDa SecA fragment in the absence and
presence of this mAb by titration with increasing concentra-
tions of AMP-PNP or ADP. ADP did not induce the
protection of a 30-kDa fragment (results not shown). The
protection of the 30-kDa fragment is completely abolished
by mAb 300-1K5 (Figure 8, closed circles), indicating that
the mAb interferes with the membrane insertion of SecA.
Trp fluorescence studies demonstrate that NBS-I binds AMP-
PNP with similar affinity as ADP (18). The induction of
the protection of the 30-kDa fragment occurs at a much
higher AMP-PNP concentration (open circles) than needed
to occupy NBS-I only. This implies that both NBS-I and
NBS-II have to be occupied by AMP-PNP.
FIGURE 6: Effect of the mAb on the SecA translocation ATPase
activity. The activity is expressed as a percentage of the translo-
cation ATPase activity of SecA in YEG+ IMV in the absence of
mAb. MAb 300-1K5 IgG (b) and Fab (O) (n ) 2). The inset shows
the effect of mAb IgG 300-1K5, 322-1K1, and 323-1K1 on the
translocation ATPase activity of SecA in wild-type IMV. The effect
of mAb 322-1K1 and 323-1K1 was assayed at a higher concentra-
tion to compensate for the lower SecA binding affinity. The activity
is expressed as a percentage of the translocation ATPase activity
of SecA in the absence of mAb (n ) 4). The SecA concentration
was 0.085 íM for both experiments. FIGURE 7: SecA membrane insertion is inhibited by mAb 300-1K5, but not by the other mAbs. Protection of a 125I-labeled 30-
kDa fragment of SecA against proteolytic digestion was used as a
measure for the insertion of 125I-SecA (16 nM) in urea treated E.
coli SecYEG+ vesicles in translocation buffer containing SecB and
proOmpA. Incubation at 0 °C with 1 mM AMP-PNP (A, B),
incubation at 37 °C with 1 mM ATP (C), and incubation at 37 °C
with 1 mM AMP-PNP (D). Samples were incubated for 30 min in
the presence or absence of mAb IgG (48 nM). The formation of
the 30-kDa fragment is expressed as a percentage of the control
that was incubated in the absence of mAbs (n ) 2). C1 and C2 in
panel A show the protection of the 30-kDa fragment in the absence
of nucleotide and vesicles, respectively.
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Next, the effect of the mAbs on the de-insertion reaction
of SecA was addressed. 125I-SecA was allowed to insert into
the membrane in the presence of AMP-PNP for 20 min.
Subsequently, the mAbs were added, and the incubation of
the sample was continued. Alternatively, an excess of
unlabeled SecA which competes with the 125I-SecA for
insertion (24) was added. Within 5 min of the addition of
a 4-fold excess of mAb 300-1K5 IgG, about 55% of the
labeled SecA was de-inserted, whereas addition of a 12-fold
excess of unlabeled SecA de-inserted only 30% of the
inserted 125I-SecA (Figure 9). MAbs 322-1K1 and 323-1K1
had a similar effect as buffer on the de-insertion of SecA. A
12.5-fold excess of 300-1K5 Fab also stimulated the de-
insertion of SecA, although a 2.5-fold excess stimulated the
insertion reaction (results not shown). This corresponds to
the effect of the 300-1K5 Fab on the translocation ATPase
activity of SecA (Figure 6). The reversal of the insertion
by mAb 300-1K5 in the presence of ATP was again
somewhat slower than in the presence of AMP-PNP (results
not shown). Since the mAb 300-1K5 more rapidly and more
efficiently affects the membrane de-insertion of 125I-labeled
SecA as compared to the replacement reaction in the presence
of an excess of unlabeled SecA, it is concluded that the mAb
actively reverses the membrane insertion of SecA.
MAb 300-1K5 Specifically Stimulates Membrane De-
insertion of SecA. To check whether the stimulation of the
de-insertion of the 30-kDa fragment occurs concomitantly
with the dissociation of SecA from the membrane, the effect
of the mAbs on the release of SecA from the membrane was
studied. YEG+ vesicles were incubated with 125I-SecA in
the presence of ATP or AMP-PNP and subsequently
centrifuged through a sucrose cushion to remove unbound
material. Vesicles were resuspended in the presence of
unlabeled SecA or mAbs and incubated for 10 min at 37
°C. The dissociated SecA was separated from the vesicles
by centrifugation through a sucrose cushion. In the presence
of AMP-PNP and unlabeled SecA, mAb 300-1K5 IgG or
Fab released 45% of the SecA from the membrane, whereas
mAbs 322-1K1 or 323-1K1 had similar effects as incubation
in buffer (Figure 10A). This shows that mAb 300-1K5 not
only stimulates SecA membrane-deinsertion but also pro-
motes the release of SecA from the membrane. MAb 300-
1K5 IgG in the presence of ATP did not dissociate SecA
from the membranes in the time course of the experiment
whereas 300-1K5 Fab did (Figure 10B). In view of the
overall slower effects on SecA insertion and de-insertion of
this mAb in the presence of ATP as compared to AMP-
PNP, this result suggests that the epitope for mAb 300-1K5
is more accessible in the AMP-PNP than in the ATP inserted
state of SecA.
Surface Plasmon Resonance Detection of Nucleotide-
Induced Conformational Changes of Soluble and Membrane
Inserted SecA. The ADP- and AMP-PNP-bound states of
SecA differ in conformation and compactness (18). The
AMP-PNP-bound state is more extended than the ADP-
bound state. To investigate whether mAb 300-1K5 has a
preference for either of these conformations of SecA, the
mAb was immobilized on a sensor. The binding of SecA
or YEG+ IMV to the 300-1K5-sensor was followed as a
function of resonance units (RU) using the SPR technique.
The variation in the experiments (n ) 4-10) was less than
1% for the ADP-bound conformations, and 7% and less than
1% for the AMP-PNP-bound conformation of soluble SecA
and SecA in vesicles, respectively. The decrease in repro-
FIGURE 8: AMP-PNP-induced formation of the protected 30-kDa
fragment is inhibited by mAb 300-1K5. The amount of 125I-labeled
30-kDa SecA fragment as a function of the AMP-PNP concentration
in the absence (O) or presence (b) of mAb 300-1K5. After 10 min
of preincubation at 37 °C, AMP-PNP (0.01-10 000 íM) was added
to urea-treated E. coli YEG+ vesicles in translocation buffer
containing SecB, proOmpA, and 16 nM 125I-SecA and as indicated
48 nM 300-1K5 IgG. Reactions were further incubated for 20 min
at 37 °C (n ) 2), and subsequently digested with proteinase K (1
mg/mL) and analyzed by Phosphorimaging as described.
FIGURE 9: SecA membrane de-insertion is stimulated by mAb 300-
1K5. Protection of a 30-kDa fragment of 125I-SecA against
proteolytic digestion was used as a measure for the de-insertion of
125I-SecA (16 nM) in urea-treated E. coli SecYEG+ vesicles in
translocation buffer containing SecB and proOmpA. Samples were
incubated at 37 °C in the presence of 1 mM AMP-PNP for 19 min
(100%), and incubation proceeded for the indicated times in the
presence of buffer (O) or a 12-fold molar excess of unlabeled SecA
(b) or a 4-fold excess of mAb 300-1K5 (9) or 323-1K1 IgG (2).
The amount of 30-kDa fragment was visualized by Phosphorim-
aging (A) and quantitated as a percent of the amount present after
19 min incubation in the presence of AMP-PNP (B).
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ducibility in the presence of AMP-PNP in the absence of
vesicles is probably caused by aggregation of SecA. At
identical SecA concentrations applied, the number of bound
resonance units is 25% higher for the AMP-PNP-bound SecA
than for the ADP-bound SecA (Figure 11A). The association
rate is the same for both SecA conformations, while the
dissociation rates differ by a factor 1.5 (Table 4). This does
not account for the 25% difference in resonance units. SPR
is measured as the change in surface plasmon angle (ı) at
which resonance occurs. Resonance occurs if the plasmon
wave vector (ksp, eq 1) is equal to the light wave vector of
the incident light. The surface plasmon wave vector is
proportional to the thickness of the layer containing the
immobilized ligand and bound analyte, and to the dielectric
constant or to the refractive index of the analyte (41).
Changes on the surface of the sensor, will change the surface
plasmon wave vector and therefore the angle at which
resonance occurs (eq 2). Because most biological polymers
have a refractive index between 1.5 and 1.6 (43), the
maximum change in refractive index would be 6.7%. This
would cause a change in the surface plasmon angle of about
16% (eq 2). The change in resonance signal is therefore
more likely an indication that the AMP-PNP-bound SecA
has a significantly larger hydrated volume than the ADP-
bound SecA, thereby changing the refractive index as well
as the thickness of the layer. Similar changes in hydrated
volume have been observed for B. subtilis SecA (18).
SecA associates with IMV in the presence of ADP, but
does not insert in the membrane to the extent that the 30-
kDa fragment is protected against proteinase K digestion,
whereas it does in the presence of AMP-PNP (24). To access
whether the membrane-bound SecA has a nucleotide-
dependent conformation similar to SecA in solution, YEG+
IMV containing intrinsically bound SecA in the presence of
ADP or AMP-PNP were injected in the 300-1K5 sensor
compartment, and the association was followed for 120 s as
described above. The association rate of AMP-PNP YEG+
vesicles is twice as fast as that of ADP YEG+ vesicles,
whereas the dissociation rates are the same (Table 4). This
is primarily due to the combined binding of SecA and
vesicles as a consequence of the AMP-PNP-induced mem-
brane inserted state of SecA, adding more mass. In the
presence of ADP, the SecA seems to dissociate rapidly from
the vesicles during the association with 300-1K5 (Figure
11B). The dissociation phase of the SecA inserted in the
vesicles in the presence of AMP-PNP is again a combined
effect of a very fast dissociation of the vesicles from SecA
FIGURE 10: Release of SecA from the membrane is stimulated by
mAb 300-1K5 IgG (white bars) and Fab (gray bars). Urea-treated
E. coli SecYEG+ vesicles were first incubated with 125I-labeled
SecA (16 nM), and the vesicles with bound SecA were isolated by
centrifugation through a sucrose cushion. The vesicles were
subsequently diluted in buffer with AMP-PNP (A) or with ATP
(B) at 37 °C in the absence and presence of SecA, mAb 300-1K5,
or mAb 322-1K1. After 10 min incubation, the amount of
membrane-associated and released SecA was determined after
separation of the samples in a pellet and supernatant fraction by
centrifugation through a sucrose cushion. The amount of released
SecA is expressed as the percentage of total membrane bound SecA.
FIGURE 11: Surface plasmon resonance sensogram of the binding
of 120 nM SecA (A) or 0.425 mg/mL YEG+ IMV (upper
sensograms in panel B) or 0.25 mg/mL urea-treated YEG+ IMV
(lower sensograms in panel B) in the presence of 1.6 mM AMP-
PNP (black lines) or ADP (gray lines). The curves illustrate the
association and dissociation as a function of time. The concentration
of SecA present in the samples containing YEG+ vesicles was 90
nM. The sensograms of aspecific binding of SecA or YEG+ IMV
to the sensor dextran layer were subtracted. The sensograms are
the average of 4-10 experiments.
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and a much slower dissociation of SecA from the mAb. The
epitope located between amino acid residues 720-790 of
300-1K5 is apparently at least partly accessible in the
membrane inserted state of SecA. No dissociation phase of
the ADP YEG+ vesicles is observed because the vesicles
did not remain bound to SecA during the association phase.
After a dissociation period of 200 s, the resonance signal is
still 22% higher for AMP-PNP-bound SecA than for ADP-
bound SecA, indicating similar conformations as described
above.
Treatment of IMV with urea removes approximately 70%
of the membrane-associated proteins (9), but leaves some
of the SecA membrane-bound in a translocation competent
form (8). The immobilized 300-1K5 binds only minor
amounts of the urea-treated YEG+ vesicles (lower traces in
Figure 11B). Normalizing the protein content of the vesicles
to the YEG complex present in the urea-treated and non-
treated vesicles, the amount of specifically bound SecA in
the urea-treated vesicles is about 13% of the amount bound
in the nontreated vesicles. These data indicate that mAb
300-1K5 does not discriminate between the ADP- and AMP-
PNP bound conformational states of SecA, and that the
epitope present in the C-domain of SecA is accessible to
the mAb both in the membrane-surface associated and
inserted states.
DISCUSSION
In this paper, we describe the production of monoclonal
antibodies against five different epitopes of SecA and their
effect on SecA preprotein translocation. All mAbs recog-
nized purified native SecA and, to a lower extent, denatured
SecA. The mAbs, apart from 322-1K1, recognize IMV-
bound SecA on a dot immunoblot. In the case of the
membrane associated/inserted SecA, this determination is
more complex since SecA can easily dissociate from the
vesicles during the incubation procedure, for instance due
to disruption of the membranes while they bind to the
supporting material. No reliable indication could be obtained
that mAb 323-1K1 or mAb 322-2E9 was able to bind the
membrane inserted SecA. As measured by surface plasmon
resonance, the SecA association rate of these mAb was on
the order of 104 s-1 M-1, and may be too slow to effectively
compete with the membrane association of SecA. In the
absence of ATP, SecA already has a KD of 40 nM for
vesicles (3). Alternatively, binding of the mAb to the
epitopes may have little effect on the activity of SecA.
Inhibition of the Translocation of proOmpA by MAb 300-
1K5. The mAb 300-1K5 inhibits the translocation of
proOmpA and the translocation ATPase activity of SecA,
but not its endogenous ATPase activity. It recognizes an
epitope which includes at least several amino acids between
positions 720 and 790. SecA mutants which have lost more
than the last 70 carboxy-terminal amino acids are not able
to translocate preproteins in ViVo (38), and mutants lacking
the last 66 amino acids are severely impaired in protein
translocation (44). A carboxy-terminal deletion up to amino
acid residue 720 does impair the translocation but not the
endogenous ATPase activity (38). The carboxyl terminus
is apparently not required for the ATPase activity of SecA,
but rather for the coupling of ATP hydrolysis to preprotein
translocation. As demonstrated by the surface plasmon
resonance experiments, mAb 300-1K5 is able to bind and
recognize both the ADP bound and the more extended AMP-
PNP bound conformation of SecA, suggesting that nucleotide
binding is not seriously impaired by the mAb. The carboxyl
terminus has also been reported to be involved in the binding
of SecB (45; P. Fekkes, unpublished results). The inhibition
of preprotein translocation by mAb 300-1K5 is not dependent
on the presence of SecB (results not shown), implying that
SecB is clearly not involved.
Accessibility of the Epitope of MAb 300-1K5. The
inhibition of the proOmpA translocation is a consequence
of the inability of SecA to insert into the cytoplasmic
membrane in the presence of the antibody. The mAb also
stimulated the de-insertion and the dissociation of SecA from
the membrane. It has been proposed that SecA contains at
least two membrane associating domains, possibly located
between amino acid residues 64 and 239 and amino acids
831-901 (9, 38, 42). The epitope of mAb 300-1K5 does
not fall within this range, but is part of the 30-kDa carboxy-
terminal fragment (amino acids 610 to approximately 870)
that has been shown to insert upon ATP binding (26). This
region just precedes the proteolytic site in the vicinity of
amino acid residue 850 of SecA that has been shown to be
accessible from the periplasmic side of the membrane (8),
consistent with the notion that part of the C-domain of SecA
inserts into the membrane (26). Since mAb 300-1K5 is able
to bind the membrane inserted state of SecA, it can be
concluded that its epitope is not concealed by the membrane
or by the integral membrane subunits of the translocase
during at least part of the preprotein translocation process.
The distribution between the membrane and cytosolic
states of SecA is likely a dynamic process of which the
equilibrium is affected by nucleotides (24, 25). ADP directs
the protein to the surface-bound state or cytosolic state,
whereas ATP favors the membrane inserted state. Release
of SecA from inner membranes can be induced by the
addition of an excess of unlabeled SecA (24, 14). This
process is dependent on ATP hydrolysis (24) but not on
preprotein translocation (14). The amount of SecA that can
be released from these membranes is dependent on the
method of SecA depletion, i.e., urea treatment (24) or
depletion of the SecA during growth of a secA temperature-
sensitive strain (14). Urea removes about 70% of the
proteins associated with the membrane (9). It is feasible
that this treatment removes or inactivates a component
needed for the stable insertion of SecA. We used urea treated
membranes reconstituted with 125I-SecA to monitor the de-
insertion and the release of SecA from the membrane. The
mAb 300-1K5 stimulated both processes far more efficiently
Table 4: Kinetic Association and Dissociation Rates of the SecA and YEG+ IMV Interaction with 300-1K5 IgG Immobilized on a
CM5-Sensor
sample ka (s-1 M-1) kd (s-1) KD (nM)
SecA AMP-PNP 1.22  105 ( 2.56  104 2.95  10-3 ( 1.52  10-4 24
SecA ADP 1.11  105 ( 7.93  103 4.49  10-3 ( 1.39  10-4 40
YEG+ AMP-PNP 2.14  105 ( 2.37  104 9.0 10-4 ( 3.12  10-4 4.2
YEG+ADP 1.12  105 ( 2.52  104 1.08  10-3 ( 5.37  10-5 9.6
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than an excess of SecA, indicating that the mAb actively
reverses the inserted state of SecA. The mAb also inhibits
the translocation of proOmpA by native IMV which contain
endogenous SecA, indicating that the inhibitory effect of the
mAb is not specific for the pretreatment of the membranes.
If the mAb would prevent the re-insertion of SecA in the
membrane as part of a dynamic equilibrium, it would be
expected that the reversion of the insertion of SecA is more
pronounced in the ATP-bound state than in the AMP-PNP-
bound state. Since the opposite phenomenon is observed, it
can be concluded that the mAb recognizes the membrane
inserted state of SecA, but that the accessibility of its epitope
differs between the ATP and AMP-PNP inserted states of
SecA.
The mAb inhibits insertion and stimulates de-insertion
irrespectively whether proOmpA translocation occurs (ATP)
or not (AMP-PNP). The AMP-PNP-induced insertion of
SecA does not require the presence of preprotein (25), and
therefore it also seems unlikely that mAb 300-1K5 acts by
interference with the binding of the preprotein. It seems
more likely that the mAb inhibits and reverses a conformation
of SecA which is essential for membrane insertion and which
differs from the thus far described ADP- or AMP-PNP-bound
soluble conformations.
In conclusion, we have isolated a mAb that recognizes an
epitope that is located in the carboxy-terminal 30-kDa
membrane inserting fragment of SecA. This mAb efficiently
inhibits preprotein translocation by interfering with the
membrane inserted state of SecA. These data provide further
evidence that preprotein translocation and membrane inser-
tion of the C-domain of SecA are coupled processes.
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